US20070003529A1 - Generating teeth from bone marrow cells - Google Patents

Generating teeth from bone marrow cells Download PDF

Info

Publication number
US20070003529A1
US20070003529A1 US10/546,495 US54649504A US2007003529A1 US 20070003529 A1 US20070003529 A1 US 20070003529A1 US 54649504 A US54649504 A US 54649504A US 2007003529 A1 US2007003529 A1 US 2007003529A1
Authority
US
United States
Prior art keywords
tooth
bone marrow
cell
cells
marrow cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/546,495
Other versions
US7588936B2 (en
Inventor
Paul Sharpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Odontis Ltd
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Assigned to ODONTIS LIMITED reassignment ODONTIS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHARPE, PAUL T.
Publication of US20070003529A1 publication Critical patent/US20070003529A1/en
Application granted granted Critical
Publication of US7588936B2 publication Critical patent/US7588936B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/09Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/097Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells oral mucosa cells

Definitions

  • the invention relates to the production of teeth and in particular the use of cultured bone marrow cells to form teeth.
  • Teeth are essential organs for animal survival and of obvious clinical and/or cosmetic importance. There are many instances where tooth replacement is desirable and current treatments are restricted to artificial prostheses or implants.
  • Tooth primordia explants can be cultured in vitro allowing a variety of manipulation studies including introduction of genes and/or proteins and tissue recombinations.
  • Tooth development requires the combination of cells from mesenchymal and epithelial lineages. Development of the mammalian tooth has been recognised as a model system for study of epithelial/mesenchymal interactions during organogenesis. Teeth start to develop early in mammalian embryogenesis (11 days in mice, 6 weeks in humans), from a series of reciprocal interactions between two cell types: oral epithelial cells and neural crest-derived mesenchyme cells.
  • Inductive signals for tooth development come from the epithelium whereupon the responding mesenchymal cells are programmed to become odontogenic (2).
  • Odontogenic mesenchymal cells then provide instructive signals for further tooth development (3).
  • the epithelial cells eventually give rise to ameloblasts which are responsible for enamel formation and mesenchyme cells form odontoblasts which produce dentine and cementoblasts.
  • FGF8 BMP4 and SHH are established as early instructive signals from the oral epithelium (3).
  • BMP's, FGF's and activin are among the early signals from the mesenchyme (3. 4).
  • stem cells such as embryonic stem cells requires purification and expansion of a population of cells. This involves intricate and highly skilled separation and manipulation techniques. Accordingly, a method for the provision of cells to form tooth progenitor cells for implantation which does not require separation and purification, would greatly facilitate the production of such an implant.
  • embryonic stem cells Another problem associated with the use of embryonic stem cells is the limited availability and ease with which the embryonic stem cells can be obtained.
  • Bone marrow cells are known to contain populations of stem cells and pluripotential cells which give rise to (a) haematopoietic cells and (b) stromal (mesenchymal) cells. Haematopoietic cells in the bone marrow, however, do not give rise to non-haematopoietic tissues (Wagers et al).
  • the present invention seeks to overcome at least some of the problems associated with the prior art.
  • teeth and teeth primordia can be generated using bone marrow cells.
  • adult bone marrow cells i.e. non-embryonic cells which may be obtained from a fully mature animal or an immature animal (e.g. child)
  • embryonic neural crest-derived mesenchymal cells in the production of tooth progenitor cells and more fully developed structures such as teeth primoridia and teeth.
  • bone marrow cells may be obtained from any individual, the use of such cells in therapeutic tooth formation offers (a) avoidance of problems of graft rejection, and (b) wider accessibility of the pluripotent cell component compared with embryonic stem cells.
  • bone marrow cells may be employed in the methods of the invention without the need for purification and expansion of a population of cells.
  • the present invention is advantageous since it is labour saving.
  • the present invention is advantageous since it does not involve multiple surgical tissue recombination.
  • the present invention is advantageous since it does not require the use of embryonic cells and teeth primordia/teeth may be formed entirely from non-embryonic cells.
  • the methods of the present invention may be employed to form teeth primordia/teeth entirely from non-odontogenic tissues that would not normally form teeth.
  • the invention provides a method of generating a tooth primordium using bone marrow cells, the method comprising:
  • bone marrow cells may be employed in the methods of the invention without the need for purification and expansion of a population of cells.
  • the bone marrow cells have not undergone purification for a particular cell type.
  • purification for a particular cell type we refer to any process which increases the proportion of a particular type of bone marrow cell present by removal of one or more other cell types present in the unpurified cell population.
  • the unpurified bone marrow cells have not undergone expansion to increase the proportion of a particular cell type present.
  • the unpurified bone marrow cells have undergone expansion to increase the proportion of a particular cell type present.
  • the bone marrow cells have undergone purification for a particular cell type, for example to increase the proportion of bone marrow stem cells present.
  • the bone marrow stem cells which are used in the first aspect of the invention are bone marrow stem cells. Techniques for obtaining a purified cell population will be well known to those skilled in the art.
  • the purified bone marrow cells have undergone expansion (either before or after purification; preferably after purification). In this way increased numbers of a particular cell type present may be obtained.
  • a method of generating a tooth progenitor cell comprising incubating bone marrow cells in the presence of oral epithelial inductive signals to produce a tooth progenitor cell, wherein the bone marrow cells have not undergone purification for a particular cell type.
  • the unpurified bone marrow cells have not undergone expansion to increase the proportion of a particular cell type present.
  • the unpurified bone marrow cells have undergone expansion to increase the proportion of a particular cell type present.
  • At least about 100, 500, 1000, 2500, 5000, 7500, 10000 or 15000 bone marrow cells are incubated in the presence of oral epithelial inductive signals.
  • the bone marrow cells are preferably obtained from a single individual. Alternatively, the bone marrow cells may be obtained from a number of individuals and pooled.
  • the bone marrow cells may be prepared for the induction/interaction in a number of ways. For example, they may be pelleted to form small aggregates. This may be accomplished by pelleting them onto filters. Such filters may comprise any suitable substrate, such as pregelatinised Millipore filters. For convenience, the filters may be supported by metal grids, for example as described in Ferguson et al. (1998).
  • the bone marrow cells may be pelleted into small holes made in a gel or other suitable semi-solid support.
  • the gel may be a collagen gel.
  • the gel may be Collaborative Biomedical Products' Matrigel or a similar substrate.
  • epithelium may be overlaid onto the bone marrow cells to cover the hole which is then covered with a thin layer of gel and incubated.
  • Gels used in this manner may themselves be supported by membrane(s) and/or metal grids.
  • the bone marrow cells are contacted with oral epithelial inductive signals.
  • the bone marrow cells are contacted with any combination of one, two, three or all of the following: FGF8, BMP4, SHH and WNTS.
  • the oral epithelial inductive signals may be provided by a variety of means some of which do not require the presence of embryonic oral epithelial cells.
  • a tooth progenitor cell is one which expresses certain molecular markers characteristic of tooth progenitor cells.
  • a cell would be considered to be a tooth progenitor cell if it expressed one or more tooth mesenchymal cell markers.
  • markers include Barx1. D1x2, D1x5, Msx1, Pax9, Activin ⁇ A, Lhx6, Lhx7 and others. These markers may be detected by any suitable means, such as western blotting, immunofluorescence, radioactive in situ hybridisation or other suitable means.
  • Barx-1 gene expression is principally found in the molar region of the mandible and maxilla and is present in a broad field of neural crest derived mesenchymal cells rather than being restricted to dental mesenchyme (Ferguson et al., 1998: Tissier-Seta et al., 1995).
  • Msx-1, Lef-1 and Bmp-4 are expressed in the dental mesenchyme (i.e. the condensing mesenchymal cells associated with invaginating incisor and molar epithelial tooth buds) in response to epithelial signalling (Ferguson et al., 1998; Mackenzie et al., 1991; Kratochwil et al., 1996; Vainio et al., 1993).
  • Dlx-2 expression is principally found in mesenchymal cells immediately surrounding the epithelial bud, but is also present in the dental epithelium on the buccal side of the buds (Ferguson et al., 1998; Thomas et al., 1995; Qui et al., 1997).
  • Pax-9, Lhx6 and Lhx7 are expressed in early tooth mesenchyme prior to bud formation and subsequently in condensing mesenchyme at the bud stage (Ferguson et al., 1998; Neubüser et al., 1997).
  • Gli-3 is expressed in the mesenchyme from E10. 5. At the bud and cap stage Gli-3 expression is slightly more localised than Par-9 expression, and is concentrated in the dental papilla and dental follicle (Ferguson et al, 1998; Hardcastle and Sharpe, 1998).
  • Syndecan-1 a cell surface heparin sulphate proteoglycan is transiently expressed in the dental mesenchyme and is thought to regulate dental mesenchymal cell condensation beneath the invaginating dental epithelium (Ferguson et al., 1998; Thesleff et al., 1996).
  • Tgf ⁇ -1 is found in the dental mesenchyme and weakly in the epithelium of the incisors and only appears in the molars in the dental epithelium at the cap stage (Ferguson et al., 1998; Vaahtokari et al., 1991).
  • Tgf ⁇ -3 expression is widespread in the mesenchyme of the face, but its expression appears to be substantially absent from the condensing mesenchymal cells immediately adjacent to the epithelial buds of incisors and molars (Ferguson et al., 1998; Chai et al., 1994).
  • Incubation with the oral epithelial inductive signals is for a time sufficient to produce the tooth progenitor cell.
  • this time is at least about 12 hours.
  • the time is between 12 and 82 hrs, preferably between 12 and 72 hours.
  • the time is between 12 and 24 hours, 12 and 36 hours or 12 and 48 hours.
  • the oral epithelial inductive signals may be provided in various ways including: (i) using embryonic oral epithelial cells, (ii) using cells which are not embryonic oral epithelial cells but which express oral epithelial inductive signals and which thereby emulate the signalling characteristics of embryonic oral epithelial cells; and (iii) using purified protein.
  • the method comprises incubating the bone marrow cells in the presence of one or more embryonic oral epithelial cells to produce the tooth progenitor cell.
  • the bone marrow cells are incubated in the presence of embryonic oral epithelium.
  • odontogenic epithelial cells may be produced from cultured cells which may be engineered to possess characteristics of embryonic oral epithelium, thereby allowing replacement of embryonic oral epithelium with engineered epithelium.
  • Examples of cells which may replace the role of embryonic oral epithelial cells in tooth progenitor production are provided in WO 01/60981 and include immortalised cell lines (e.g. epithelial cells derived from immortalised lines of tooth epithelial cells) and ES cell-derived (i.e. cultured cell derived) epithelial cells.
  • the bone marrow cells are incubated in the presence of one or more inductive odontogenic cells which emulate the signalling characteristics of embryonic oral epithelial cells to produce the tooth progenitor cell.
  • the inductive odontogenic cells may be produced from non-oral epithelial cells (e.g. epithelial cells derived from immortalised lines of tooth epithelial cells).
  • the odontogenic cells are produced from an immortalised cell line or a stem cell (e.g. ES cell).
  • the inductive odontogenic cells preferably express one, two, three, four or all of the following: FGF8, BMP4, SHH, Pitx2 and Islet1.
  • molecular markers may be analysed to determine whether the signalling properties of early oral epithelium are well established. For instance, expression of FGF8, BMP4, SHH and Pitx2 (the earliest marker of oral epithelium) may be analysed to determine which cells are likely to be able to replace oral epithelial cells.
  • inductive signalling molecules FGF8, BMP4, SHH etc.
  • the combination of secreted signals necessary to induce odontogenesis in bone marrow cells may alternatively be provided using purified protein such as by using the bead delivery system as described in WO 01/60981.
  • the bone marrow cells may be incubated in the presence of protein-containing beads or protein-coated beads to provide oral epithelial inductive signals to produce the tooth progenitor cell.
  • protein-containing beads or protein-coated beads to provide oral epithelial inductive signals to produce the tooth progenitor cell.
  • suitable concentrations of the proteins will readily be able to devise suitable concentrations of the proteins.
  • odontogenic inducing capacity resides in the tooth progenitor cell and naive epithelial cells respond to signals from the tooth progenitor cell and allows tooth development. If the growth medium used in the cultures does not contain the factors required for the production of an odontogenic epithelium, the culture media may be supplemented with the necessary factors.
  • tooth progenitor cells according to the second aspect of the invention may be used for the production of tooth primordia, or more fully developed teeth.
  • teeth primordia is well known in the art and refers to structures that can develop into fully-formed teeth.
  • Incubation of the tooth progenitor cell in the presence of one or more epithelial cells is for a time sufficient to produce a tooth primordium. Preferably, this time is at least about 12 hours. Preferably, the tooth progenitor cell is incubated in the presence of oral epithelium.
  • the one or more epithelial cells are oral epithelial cells; embryonic epithelial cells; oral, embryonic epithelial cells; or are epithelial cells derived from stem cells (embryonic stem (ES) cells or adult stem cells) or an immortalised cell line.
  • stem cells embryonic stem (ES) cells or adult stem cells
  • a third aspect of the present invention provides a tooth progenitor cell obtainable by a method according to the second aspect of the invention.
  • a fourth aspect of the present invention provides a tooth primordium obtainable by a method according to the first aspect of the invention.
  • the tooth primordia of the first aspect of the invention can be cultured in vitro allowing a variety of manipulation studies including introduction of genes and/or proteins and tissue recombinations. Most significantly, manipulated tooth primordia can be transferred to renal capsules of adult animals (such as humans and mice) to produce conditions for development of adult teeth.
  • a fifth aspect of the present invention provides a method for generating a tooth the method comprising:
  • the method of the fifth aspect of the invention is carried out on an individual in need of tooth replacement.
  • the method of the fifth aspect of the invention is carried out on a human patient.
  • a sixth aspect of the present invention relates to the use of a tooth primordium according to the first aspect of the invention in the manufacture of a medicament for generating a tooth.
  • the tooth primordium is used in the manufacture of a medicament for generating a tooth in a subject in need of tooth replacement, preferably a human patient.
  • the methods of the present invention are carried out with human or murine cells.
  • the present invention may be used for tooth replacement, particularly for murine or human tooth replacement. It is known that embryonic tooth primordia can develop and grow normally in the adult environment, for example using renal transfers (1,4). It seems that sites such as the adult kidney and eye provide a suitable environment largely by allowing an adequate blood supply.
  • the tooth that develops in situ is of the correct shape and size.
  • a number of the genes that determine tooth shape are known, and by manipulation of these genes it is possible to change tooth shape (1,4,7,8). Similarly, it is shown experimentally that modulation of signalling events leads to alteration of tooth size.
  • the methods of the present invention may be advantageously applied to the replacement of the embryonic environment usually required for tooth development by an adult environment, such as via implantation of tooth progenitor cells or structures resulting therefrom into an adult jaw for development. Teeth produced/transplanted according to the present invention continue to grow and develop when implanted into the jaw bone, and become attached thereto.
  • the present invention provides for cells to be directed to follow an odontogenic pathway in culture and subsequently develop into mature teeth when implanted into mammalian jaw or kidney.
  • bone marrow cells can be programmed by exposure to odontogenic signals (eg. from oral epithelium) in culture to subsequently form teeth on implantation (eg. renal implantation, or implantation into jaw).
  • odontogenic signals eg. from oral epithelium
  • teeth on implantation eg. renal implantation, or implantation into jaw.
  • tooth primordia attach and develop successfully following implantation into the jaw.
  • markers include Pitx2, p21, Wnt7b and others. These markers may be detected by any suitable means, such as western blotting, immunofluorescence, radioactive in situ hybridisation or other suitable means.
  • Bmp-4 is initially expressed in the dental epithelium, but expression shifts to the mesenchyme around the tooth buds from E13. 5 (Aberg et al., 1997). At E13. 5 mesenchymal Bmp-4 expression is found only in lower incisors, which are the most advanced developmentally at this stage, whereas expression persists in the epithelium of upper incisors and molars (Ferguson et al., 1998).
  • Shh is expressed in the epithelial thickening of early tooth germs and is thought to be an important component of the signals that pass from the epithelium to the underlying mesenchyme at this early stage, inducing gene expression in the mesenchyme (Bitgood and McMahon, 1995; Thesleff and Sharpe, 1997).
  • Shh is down-regulated but transcripts reappear in the epithelial cells that constitute the enamel knot, a transient signalling centre that arises in the dental epithelium at the late bud stage of tooth development (Ferguson et al., 1998; Vaahtokari et al, 1996).
  • CD44 and Otlx-2 are expressed more widely in the oral epithelium than Shh (Ferguson et al., 1998; Mucchielli et al, 1997).
  • CD44 encodes the hyaluronan receptor and Otlx-2 is the murine homologue of the human gene which when mutated, causes the disease known as Rieger syndrome in which teeth are absent (Semina et al; 1996).
  • Follistatin is an activin-binding protein that has been shown to inhibit the activity of activin (Michel et al., 1993; De Winter et al, 1996). The expression pattern of Follistatin may be examined by in situ hybridisation analysis (Ferguson et al., 1998).
  • Follistatin expression is found in tooth germ epithelial cells immediately adjacent to activin expressing cells from El 1. 5. At later stages, follistatin transcripts are restricted to the columnar-shaped cells that form the outermost layer of the epithelial bud, while the central core of epithelial cells are follistatin-negative (Ferguson et al., 1998). Follistatin is therefore expressed in the tooth epithelium adjacent to and in a complementary pattern to activin in the tooth mesenchyme.
  • FIG. 1 Tooth structure observed at the implantation site.
  • Bone marrow cells were collected from tibiae and femora of 6-9-week-old female wild-type mice. Five mice were killed by cervical dislocation, and femurs and tibiae were aseptically removed and dissected free of adherent tissue. Both ends of the bone were cut, and the bone cavity was flushed out with culture medium slowly injected at the end of the bone using a sterile 21-gauge needle. Bone marrow cells were subsequently suspended in minimal essential medium (MEM; Sigma Chemical Co., St.
  • MEM minimal essential medium
  • Mandibles of embryos were dissected out in DMEM with glutamax-1.
  • the epithelium was isolated following incubation in a solution of Dispase (GIBCO BRL) made up in calcium- and magnesium-free PBS at 2 U/ml for 10-15 min at 37° C. After incubation the tissues were washed in DMEM with 10% FCS, and the epithelium was mechanically separated using fine tungsten needles.
  • the bone marrow cells were cultured as described in Example 1 and removed by brief exposure to trypsin, collected in medium, centrifuged, washed again in medium and centrifuged twice. The cells were then counted and resuspended at two million cells in 50-100 ⁇ l medium. These stem cells were then centrifuged for 10-20 sec at 10.000 g to form a pellet which was then placed on a transparent Nucleopore membrane filters (0.1- ⁇ m-pore diameter; Costar), pre-soaked in 1% gelatin solution. Excess medium was removed from around the pellet. Cell pellets were incubated on the membrane filter supported by a metal grid for 10-15 min at 37° C. following the Trowel technique as modified by Saxén (Trowel 1959, Saxén 1966) at 37° C. with an atmosphere of 5% CO 2 /95% air and 100% humidity.
  • 3-4 epithelia prepared as described in Example 2, were then placed over the cell pellet. The co-cultures were incubated for a further 3 days.

Abstract

The present invention is based on the discovery that teeth primordia can be generated using bone marrow cells and that bone marrow cells may be employed to generate teeth without the need for purification and expansion of a population of cells.

Description

    FIELD OF THE INVENTION
  • The invention relates to the production of teeth and in particular the use of cultured bone marrow cells to form teeth.
  • All documents mentioned herein are incorporated herein in their entirety.
  • BACKGROUND TO THE INVENTION
  • Teeth are essential organs for animal survival and of obvious clinical and/or cosmetic importance. There are many instances where tooth replacement is desirable and current treatments are restricted to artificial prostheses or implants.
  • Tooth primordia explants can be cultured in vitro allowing a variety of manipulation studies including introduction of genes and/or proteins and tissue recombinations.
  • Tooth development requires the combination of cells from mesenchymal and epithelial lineages. Development of the mammalian tooth has been recognised as a model system for study of epithelial/mesenchymal interactions during organogenesis. Teeth start to develop early in mammalian embryogenesis (11 days in mice, 6 weeks in humans), from a series of reciprocal interactions between two cell types: oral epithelial cells and neural crest-derived mesenchyme cells.
  • Inductive signals for tooth development come from the epithelium whereupon the responding mesenchymal cells are programmed to become odontogenic (2).
  • Odontogenic mesenchymal cells then provide instructive signals for further tooth development (3). The epithelial cells eventually give rise to ameloblasts which are responsible for enamel formation and mesenchyme cells form odontoblasts which produce dentine and cementoblasts.
  • The identity of these different instructive signals has been revealed by gene expression studies and implantation experiments. FGF8, BMP4 and SHH are established as early instructive signals from the oral epithelium (3). BMP's, FGF's and activin are among the early signals from the mesenchyme (3. 4).
  • Prior art approaches to the production of tooth primordia have included in vitro tissue recombination. In this approach, two different tissue types are independently dissected from the animal embryo, and these tissues are recombined in the laboratory. Signals from one may then induce formation of tooth primordia in the other. This is a labour intensive process carried out by highly trained workers involving a great deal of surgical skill.
  • In an alternative approach, Young et al. has showed that cells dissociated from early tooth buds when cultured on a matrix and implanted into an adult animal can form teeth, indicating the presence of both epithelial and mesenchymal dental stem cells (Young, C. S., Terada, S., Vacanti, J. P., Honda, M., Bartlett, J. D., Yelick, P. C. (2002) Tissue engineering of complex tooth structures on biodegradable polymer scaffolds. J. Dent. Res. 81, 695-700).
  • For human therapeutic purposes the major drawback is the potential problem of graft rejection, thus requiring either immunosuppression of host (recipient), or genetic manipulation of the graft cells to circumvent rejection, and the difficulty of obtaining the cells. Therefore the use of cells derived exclusively from each patient would avoid such rejection problems.
  • Sharpe (WO 01/60981) showed that cultured embryonic stem cells can give rise to epithelial and mesenchyme lineages, enabling the production of teeth primordia from embryonic stem cells.
  • Use of stem cells such as embryonic stem cells requires purification and expansion of a population of cells. This involves intricate and highly skilled separation and manipulation techniques. Accordingly, a method for the provision of cells to form tooth progenitor cells for implantation which does not require separation and purification, would greatly facilitate the production of such an implant.
  • Another problem associated with the use of embryonic stem cells is the limited availability and ease with which the embryonic stem cells can be obtained.
  • Adult (i.e. non-embryonic) bone marrow cells are known to contain populations of stem cells and pluripotential cells which give rise to (a) haematopoietic cells and (b) stromal (mesenchymal) cells. Haematopoietic cells in the bone marrow, however, do not give rise to non-haematopoietic tissues (Wagers et al). Mesenchymal stem cells give rise to homogeneous differentiated cell types of tissues including bone, cartilage, fat, muscle, tendon, hematopoiesis-supporting stroma, and mesangial tissues, but are not known to be capable of forming organs of composite cell lineages and those that require specific reciprocal tissue interactions, such as teeth whose development requires contributions from more than one cell lineage.
  • The present invention seeks to overcome at least some of the problems associated with the prior art.
  • SUMMARY OF THE INVENTION
  • Surprisingly, it has been discovered that teeth and teeth primordia can be generated using bone marrow cells. Accordingly, adult bone marrow cells (i.e. non-embryonic cells which may be obtained from a fully mature animal or an immature animal (e.g. child)) may replace embryonic neural crest-derived mesenchymal cells in the production of tooth progenitor cells and more fully developed structures such as teeth primoridia and teeth.
  • Since bone marrow cells may be obtained from any individual, the use of such cells in therapeutic tooth formation offers (a) avoidance of problems of graft rejection, and (b) wider accessibility of the pluripotent cell component compared with embryonic stem cells.
  • Surprisingly, it has also been discovered that bone marrow cells may be employed in the methods of the invention without the need for purification and expansion of a population of cells.
  • There are various advantages afforded by the present invention.
  • The present invention is advantageous since it is labour saving.
  • Further, the present invention is advantageous since it does not involve multiple surgical tissue recombination.
  • The present invention is advantageous since it does not require the use of embryonic cells and teeth primordia/teeth may be formed entirely from non-embryonic cells.
  • Advantageously, the methods of the present invention may be employed to form teeth primordia/teeth entirely from non-odontogenic tissues that would not normally form teeth.
  • It is envisaged that the teachings disclosed herein with respect to tooth development may be used to generate teeth in vitro and ultimately in vivo in an adult oral cavity.
  • DETAILED DESCRIPTION OF THE INVENTION
  • According to a first aspect, the invention provides a method of generating a tooth primordium using bone marrow cells, the method comprising:
    • i) incubating the bone marrow cells in the presence of oral epithelial inductive signals for a time sufficient to produce a tooth progenitor cell;
    • ii) incubating the tooth progenitor cell in the presence of at least one epithelial cell for a time sufficient to produce a tooth primordium.
  • Surprisingly, it has also been discovered that bone marrow cells may be employed in the methods of the invention without the need for purification and expansion of a population of cells. Thus, in one embodiment of the invention, the bone marrow cells have not undergone purification for a particular cell type. By “purification for a particular cell type” we refer to any process which increases the proportion of a particular type of bone marrow cell present by removal of one or more other cell types present in the unpurified cell population.
  • Preferably, the unpurified bone marrow cells have not undergone expansion to increase the proportion of a particular cell type present. Alternatively, the unpurified bone marrow cells have undergone expansion to increase the proportion of a particular cell type present.
  • In another embodiment of the invention, the bone marrow cells have undergone purification for a particular cell type, for example to increase the proportion of bone marrow stem cells present. In one embodiment of the invention the bone marrow stem cells which are used in the first aspect of the invention are bone marrow stem cells. Techniques for obtaining a purified cell population will be well known to those skilled in the art.
  • Preferably, the purified bone marrow cells have undergone expansion (either before or after purification; preferably after purification). In this way increased numbers of a particular cell type present may be obtained.
  • In a second aspect of the present invention there is provided a method of generating a tooth progenitor cell, the method comprising incubating bone marrow cells in the presence of oral epithelial inductive signals to produce a tooth progenitor cell, wherein the bone marrow cells have not undergone purification for a particular cell type.
  • Preferably, the unpurified bone marrow cells have not undergone expansion to increase the proportion of a particular cell type present. Alternatively, the unpurified bone marrow cells have undergone expansion to increase the proportion of a particular cell type present.
  • Preferably, in the first and second aspects of the invention at least about 100, 500, 1000, 2500, 5000, 7500, 10000 or 15000 bone marrow cells are incubated in the presence of oral epithelial inductive signals.
  • Methods for obtaining bone marrow cells will be well known to persons skilled in the art.
  • The bone marrow cells are preferably obtained from a single individual. Alternatively, the bone marrow cells may be obtained from a number of individuals and pooled.
  • The bone marrow cells may be prepared for the induction/interaction in a number of ways. For example, they may be pelleted to form small aggregates. This may be accomplished by pelleting them onto filters. Such filters may comprise any suitable substrate, such as pregelatinised Millipore filters. For convenience, the filters may be supported by metal grids, for example as described in Ferguson et al. (1998). The bone marrow cells may be pelleted into small holes made in a gel or other suitable semi-solid support. The gel may be a collagen gel. The gel may be Collaborative Biomedical Products' Matrigel or a similar substrate.
  • Optionally, epithelium may be overlaid onto the bone marrow cells to cover the hole which is then covered with a thin layer of gel and incubated.
  • Gels used in this manner may themselves be supported by membrane(s) and/or metal grids.
  • The bone marrow cells are contacted with oral epithelial inductive signals. Preferably, the bone marrow cells are contacted with any combination of one, two, three or all of the following: FGF8, BMP4, SHH and WNTS. As discussed below, the oral epithelial inductive signals may be provided by a variety of means some of which do not require the presence of embryonic oral epithelial cells.
  • A tooth progenitor cell is one which expresses certain molecular markers characteristic of tooth progenitor cells. For example, a cell would be considered to be a tooth progenitor cell if it expressed one or more tooth mesenchymal cell markers. Examples of such markers include Barx1. D1x2, D1x5, Msx1, Pax9, Activin βA, Lhx6, Lhx7 and others. These markers may be detected by any suitable means, such as western blotting, immunofluorescence, radioactive in situ hybridisation or other suitable means.
  • In wild type teeth at the bud stage Barx-1 gene expression is principally found in the molar region of the mandible and maxilla and is present in a broad field of neural crest derived mesenchymal cells rather than being restricted to dental mesenchyme (Ferguson et al., 1998: Tissier-Seta et al., 1995).
  • Msx-1, Lef-1 and Bmp-4 are expressed in the dental mesenchyme (i.e. the condensing mesenchymal cells associated with invaginating incisor and molar epithelial tooth buds) in response to epithelial signalling (Ferguson et al., 1998; Mackenzie et al., 1991; Kratochwil et al., 1996; Vainio et al., 1993).
  • Dlx-2 expression is principally found in mesenchymal cells immediately surrounding the epithelial bud, but is also present in the dental epithelium on the buccal side of the buds (Ferguson et al., 1998; Thomas et al., 1995; Qui et al., 1997).
  • Pax-9, Lhx6 and Lhx7 are expressed in early tooth mesenchyme prior to bud formation and subsequently in condensing mesenchyme at the bud stage (Ferguson et al., 1998; Neubüser et al., 1997).
  • Gli-3 is expressed in the mesenchyme from E10. 5. At the bud and cap stage Gli-3 expression is slightly more localised than Par-9 expression, and is concentrated in the dental papilla and dental follicle (Ferguson et al, 1998; Hardcastle and Sharpe, 1998).
  • Syndecan-1, a cell surface heparin sulphate proteoglycan is transiently expressed in the dental mesenchyme and is thought to regulate dental mesenchymal cell condensation beneath the invaginating dental epithelium (Ferguson et al., 1998; Thesleff et al., 1996).
  • Tgfβ-1 is found in the dental mesenchyme and weakly in the epithelium of the incisors and only appears in the molars in the dental epithelium at the cap stage (Ferguson et al., 1998; Vaahtokari et al., 1991).
  • Tgfβ-3 expression is widespread in the mesenchyme of the face, but its expression appears to be substantially absent from the condensing mesenchymal cells immediately adjacent to the epithelial buds of incisors and molars (Ferguson et al., 1998; Chai et al., 1994).
  • Incubation with the oral epithelial inductive signals is for a time sufficient to produce the tooth progenitor cell. Preferably, this time is at least about 12 hours. Preferably, the time is between 12 and 82 hrs, preferably between 12 and 72 hours. Preferably, the time is between 12 and 24 hours, 12 and 36 hours or 12 and 48 hours.
  • As discussed in WO 01/60981, the oral epithelial inductive signals may be provided in various ways including: (i) using embryonic oral epithelial cells, (ii) using cells which are not embryonic oral epithelial cells but which express oral epithelial inductive signals and which thereby emulate the signalling characteristics of embryonic oral epithelial cells; and (iii) using purified protein.
  • In one embodiment of the first and second aspects of the invention, the method comprises incubating the bone marrow cells in the presence of one or more embryonic oral epithelial cells to produce the tooth progenitor cell.
  • Preferably, the bone marrow cells are incubated in the presence of embryonic oral epithelium.
  • As established in WO 01/60981, the role of embryonic oral epithelial cells in providing oral epithelial inductive signals may be replaced by using, inter alia, inductive odontogenic cells which emulate the signalling characteristics of embryonic oral epithelium. WO 01/60981 discloses that odontogenic epithelial cells may be produced from cultured cells which may be engineered to possess characteristics of embryonic oral epithelium, thereby allowing replacement of embryonic oral epithelium with engineered epithelium. Examples of cells which may replace the role of embryonic oral epithelial cells in tooth progenitor production are provided in WO 01/60981 and include immortalised cell lines (e.g. epithelial cells derived from immortalised lines of tooth epithelial cells) and ES cell-derived (i.e. cultured cell derived) epithelial cells.
  • Accordingly, in an alternative embodiment of the first and second aspects of the invention, the bone marrow cells are incubated in the presence of one or more inductive odontogenic cells which emulate the signalling characteristics of embryonic oral epithelial cells to produce the tooth progenitor cell.
  • The inductive odontogenic cells may be produced from non-oral epithelial cells (e.g. epithelial cells derived from immortalised lines of tooth epithelial cells). Preferably, the odontogenic cells are produced from an immortalised cell line or a stem cell (e.g. ES cell).
  • The inductive odontogenic cells preferably express one, two, three, four or all of the following: FGF8, BMP4, SHH, Pitx2 and Islet1.
  • As discussed in WO 01/60981, molecular markers may be analysed to determine whether the signalling properties of early oral epithelium are well established. For instance, expression of FGF8, BMP4, SHH and Pitx2 (the earliest marker of oral epithelium) may be analysed to determine which cells are likely to be able to replace oral epithelial cells.
  • Methods for testing the odontogenic inducing capacity of cell lines are also disclosed in WO 01/60981.
  • As discussed in WO 01/60981, if the epithelial cells do not properly induce odontogenesis the expression of inductive signalling molecules (FGF8, BMP4, SHH etc.) may be assayed in collagen explant cultures and any missing signals are replaced either by purified proteins on beads or by electroporation of gene expression constructs.
  • The combination of secreted signals necessary to induce odontogenesis in bone marrow cells may alternatively be provided using purified protein such as by using the bead delivery system as described in WO 01/60981.
  • Accordingly, in another embodiment of the first and second aspects of the invention the bone marrow cells may be incubated in the presence of protein-containing beads or protein-coated beads to provide oral epithelial inductive signals to produce the tooth progenitor cell. Persons skilled in the art will readily be able to devise suitable concentrations of the proteins.
  • Once a tooth progenitor cell has been generated, odontogenic inducing capacity resides in the tooth progenitor cell and naive epithelial cells respond to signals from the tooth progenitor cell and allows tooth development. If the growth medium used in the cultures does not contain the factors required for the production of an odontogenic epithelium, the culture media may be supplemented with the necessary factors.
  • Advantageously, tooth progenitor cells according to the second aspect of the invention may be used for the production of tooth primordia, or more fully developed teeth.
  • The term “tooth primordia” is well known in the art and refers to structures that can develop into fully-formed teeth.
  • Incubation of the tooth progenitor cell in the presence of one or more epithelial cells is for a time sufficient to produce a tooth primordium. Preferably, this time is at least about 12 hours. Preferably, the tooth progenitor cell is incubated in the presence of oral epithelium.
  • Preferably, the one or more epithelial cells are oral epithelial cells; embryonic epithelial cells; oral, embryonic epithelial cells; or are epithelial cells derived from stem cells (embryonic stem (ES) cells or adult stem cells) or an immortalised cell line.
  • A third aspect of the present invention provides a tooth progenitor cell obtainable by a method according to the second aspect of the invention.
  • A fourth aspect of the present invention provides a tooth primordium obtainable by a method according to the first aspect of the invention.
  • The tooth primordia of the first aspect of the invention can be cultured in vitro allowing a variety of manipulation studies including introduction of genes and/or proteins and tissue recombinations. Most significantly, manipulated tooth primordia can be transferred to renal capsules of adult animals (such as humans and mice) to produce conditions for development of adult teeth.
  • A fifth aspect of the present invention provides a method for generating a tooth the method comprising:
    • i) providing a tooth primordium produced by a method according to the first aspect of the invention;
    • ii) implanting the tooth primordium into a mammalian kidney or into a space in the oral cavity and allowing the tooth primordium to develop into a tooth.
  • Preferably, the method of the fifth aspect of the invention is carried out on an individual in need of tooth replacement.
  • Preferably, the method of the fifth aspect of the invention is carried out on a human patient.
  • A sixth aspect of the present invention relates to the use of a tooth primordium according to the first aspect of the invention in the manufacture of a medicament for generating a tooth. Preferably, the tooth primordium is used in the manufacture of a medicament for generating a tooth in a subject in need of tooth replacement, preferably a human patient.
  • Preferably, the methods of the present invention are carried out with human or murine cells.
  • The present invention may be used for tooth replacement, particularly for murine or human tooth replacement. It is known that embryonic tooth primordia can develop and grow normally in the adult environment, for example using renal transfers (1,4). It seems that sites such as the adult kidney and eye provide a suitable environment largely by allowing an adequate blood supply.
  • In addition to being able to develop a series of procedures to allow tooth replacement it is desirable that the tooth that develops in situ is of the correct shape and size. A number of the genes that determine tooth shape are known, and by manipulation of these genes it is possible to change tooth shape (1,4,7,8). Similarly, it is shown experimentally that modulation of signalling events leads to alteration of tooth size.
  • For example, inhibition of Wnt signalling leads to the development of smaller teeth (9). These observations could be advantageously employed in the methods of the present invention.
  • The methods of the present invention may be advantageously applied to the replacement of the embryonic environment usually required for tooth development by an adult environment, such as via implantation of tooth progenitor cells or structures resulting therefrom into an adult jaw for development. Teeth produced/transplanted according to the present invention continue to grow and develop when implanted into the jaw bone, and become attached thereto.
  • It is envisaged that the present invention provides for cells to be directed to follow an odontogenic pathway in culture and subsequently develop into mature teeth when implanted into mammalian jaw or kidney.
  • It is an advantage of the present invention that bone marrow cells can be programmed by exposure to odontogenic signals (eg. from oral epithelium) in culture to subsequently form teeth on implantation (eg. renal implantation, or implantation into jaw).
  • It is an advantage of the present invention that tooth primordia attach and develop successfully following implantation into the jaw.
  • Epithelial Markers
  • Examples of such markers include Pitx2, p21, Wnt7b and others. These markers may be detected by any suitable means, such as western blotting, immunofluorescence, radioactive in situ hybridisation or other suitable means.
  • Genes known to be expressed in tooth germ epithelium include Bmp-4, Sonic hedgehog (Shh), CD44, FGF8, Pitx2 and Otlx-2 genes.
  • In wild-type embryos, Bmp-4 is initially expressed in the dental epithelium, but expression shifts to the mesenchyme around the tooth buds from E13. 5 (Aberg et al., 1997). At E13. 5 mesenchymal Bmp-4 expression is found only in lower incisors, which are the most advanced developmentally at this stage, whereas expression persists in the epithelium of upper incisors and molars (Ferguson et al., 1998).
  • Shh is expressed in the epithelial thickening of early tooth germs and is thought to be an important component of the signals that pass from the epithelium to the underlying mesenchyme at this early stage, inducing gene expression in the mesenchyme (Bitgood and McMahon, 1995; Thesleff and Sharpe, 1997). At later stages, Shh is down-regulated but transcripts reappear in the epithelial cells that constitute the enamel knot, a transient signalling centre that arises in the dental epithelium at the late bud stage of tooth development (Ferguson et al., 1998; Vaahtokari et al, 1996).
  • CD44 and Otlx-2 are expressed more widely in the oral epithelium than Shh (Ferguson et al., 1998; Mucchielli et al, 1997). CD44 encodes the hyaluronan receptor and Otlx-2 is the murine homologue of the human gene which when mutated, causes the disease known as Rieger syndrome in which teeth are absent (Semina et al; 1996).
  • Follistatin is an activin-binding protein that has been shown to inhibit the activity of activin (Michel et al., 1993; De Winter et al, 1996). The expression pattern of Follistatin may be examined by in situ hybridisation analysis (Ferguson et al., 1998).
  • Follistatin expression is found in tooth germ epithelial cells immediately adjacent to activin expressing cells from El 1. 5. At later stages, follistatin transcripts are restricted to the columnar-shaped cells that form the outermost layer of the epithelial bud, while the central core of epithelial cells are follistatin-negative (Ferguson et al., 1998). Follistatin is therefore expressed in the tooth epithelium adjacent to and in a complementary pattern to activin in the tooth mesenchyme.
  • EXAMPLES
  • The present invention will now be described by way of example, in which reference is made to:
  • FIG. 1: Tooth structure observed at the implantation site.
  • Example 1 Derivation & Culture of the Murine Bone Marrow Cells
  • Bone marrow cells were collected from tibiae and femora of 6-9-week-old female wild-type mice. Five mice were killed by cervical dislocation, and femurs and tibiae were aseptically removed and dissected free of adherent tissue. Both ends of the bone were cut, and the bone cavity was flushed out with culture medium slowly injected at the end of the bone using a sterile 21-gauge needle. Bone marrow cells were subsequently suspended in minimal essential medium (MEM; Sigma Chemical Co., St. Louis, Mo.) containing 10% heat-inactivated foetal bovine serum (FBS; GIBCO BRL, Grand Island, N.Y., USA) and were maintained for 14 days in a 75-cm2 tissue flask. The medium was changed after 3 days and then subsequently every 2 days.
  • Example 2 Preparation of Oral Epithelium
  • Mandibles of embryos were dissected out in DMEM with glutamax-1. The epithelium was isolated following incubation in a solution of Dispase (GIBCO BRL) made up in calcium- and magnesium-free PBS at 2 U/ml for 10-15 min at 37° C. After incubation the tissues were washed in DMEM with 10% FCS, and the epithelium was mechanically separated using fine tungsten needles.
  • Example 3 Co-Culture of Bone Marrow Cells with Oral Epithelium
  • The bone marrow cells were cultured as described in Example 1 and removed by brief exposure to trypsin, collected in medium, centrifuged, washed again in medium and centrifuged twice. The cells were then counted and resuspended at two million cells in 50-100 μl medium. These stem cells were then centrifuged for 10-20 sec at 10.000 g to form a pellet which was then placed on a transparent Nucleopore membrane filters (0.1-μm-pore diameter; Costar), pre-soaked in 1% gelatin solution. Excess medium was removed from around the pellet. Cell pellets were incubated on the membrane filter supported by a metal grid for 10-15 min at 37° C. following the Trowel technique as modified by Saxén (Trowel 1959, Saxén 1966) at 37° C. with an atmosphere of 5% CO2/95% air and 100% humidity.
  • 3-4 epithelia, prepared as described in Example 2, were then placed over the cell pellet. The co-cultures were incubated for a further 3 days.
  • Example 4 Renal Capsule Implantation
  • The co-cultures of bone-marrow cells and oral epithelium, described in Example 3, were surgically implanted under the renal capsule of male adult mice and cultured for a further 10 days to allow tooth development. At the end of this period, the mice were sacrificed and the renal implant site examined for gross morphology. Ectopic tooth development was confirmed by decalcification of the tissue, wax embedding, staining with haematoxylin & eosin and histological examination.
  • Results
  • Tooth structures were observed at the implantation site. An example is shown in FIG. 1.
  • Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.
  • REFERENCES
    • Aberg, T., Wozney, J. and Thesleff, I. 1997. Expression patterns of BMPs in the developing mouse tooth suggest roles in morphogenesis and cell differentiation. Dev. Dyn. 210: 383-396.
    • Asashima, M., Nakano, H., Shimada, K., Kinoshita, K., Ishii, K., Shibai, H., and Ueno, N. 1990. Mesodermal induction in early amphibian embryos by activin A (erythroid differentiation factor). Roux's Arch. Dev. Biol. 198: 330-335.
    • Bitgood, M. J. & McMahon, A. P. 1995. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172: 126-138.
    • Chai, Y., Mah, A., Crohin. C. Groff, S., Bringas, P., Jr., Le, T., Santos, V. and Slavkin, H. C. 1994. Specific transforming growth factor-beta subtypes regulate embryonic mouse Meckel's cartilage and tooth development. Dev. Biol. 162: 85-103.
    • Chen, Y., Bei, M., Woo, I., Satokata, I. and Maas, R. 1996. Msx1 controls inductive signalling in mammalian tooth morphogenesis. Development 122: 3035-3044.
    • Conlon, F. 1994. A primary requirement for Nodal in the formation and maintenance of the primitive streak in the mouse. Development 120: 1919-1928.
    • Crossley, P. H. and Martin, G. R. 1995. The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. Development 121, 439-451.
    • De Winter, J. P., Ten Dijke P., De Vries, C. J. M., Van Acterberg, T. A. E., De Waele, P., Huylebroeck, D., Verschueren, K. and Van den Eijnden-van Raaij, A. J. M. 1996.
    • Follistatins neutralise activin bioactivity by inhibition of activin binding to its type II receptors. Mol. Cell Endocrinol. 116: 105-114.
    • Dohrmann, C. E. Hemmati-Brivanlou, A., Thomsen, G. H. and Fields, A. 1993.
    • Expression of activin mRNA during early development in Xenopus laevis. Dev. Biol. 157: 474-483.
    • Dyson, S. and Gurdon, J. B. 1997. Activin signalling has a necessary function in Xenopus early development. Clzrr. Biol. 7: 81-84.
    • Fainsod, A., Deissler, K., Yelin, R., Marom, K., Epstein. M., Pillemer, G., Steinbeisser, H. and Blum, M. 1997. The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-J. Alech. Dev. 63: 39-50.
    • Feijen, A., Goumans, M. J. and van den Eijnden-van Raaij. 1994. Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development 120: 3621-3637.
    • Ferguson C. A., Tucker A. S., Christiensen L., Lau A. L., Matzuk M. M. and Sharpe P. T. 1998. Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes Dev. 12: 2636-2649
    • Green, J. B. A., and Smith J. C. 1990. Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate. Nature 347: 391-394.
    • Green, J. B. C., New, H. V., and Smith, J. C. 1992. Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm. Cell 71: 731-739.
    • Grigoriou, M., Tucker, A. S., Sharpe, P. T. and Pachnis, V. 1998. Expression and regulation of Lhx6 and Lhx7, a novel subfamily of LIM homeodomain encoding genes, suggests a role in mammalian head development. Development, in press.
    • Hardcastle, Z., Mo, R., Nui, C.-c. and Sharpe, P. T. 1998. The Shh signalling pathway in tooth development: defects in Gli2 and Gli3 mutants. Development. In press.
    • Heikinheimo, K., Begue-Kirn, C., Ritvos, O., Tuuri, T. and Ruch, J. V. 1997. The activin-binding protein follistatin is expressed in developing murine molar and induces odontoblast-like cell differentiation in vitro. J Dent. Res. 76: 1625-1636.
    • Heikinheimo, M., Lawshe, A., Shackleford, G. M., Wilson, D. B. and MacArthur, C. A. 1994. Fgf-8 expression in the post-gastrulation mouse suggests roles in the development of the face, limbs and central nervous system. Mach. Dev. 48: 129-138.
    • Hemmati-Brivanlou, A., and Melton, D. A. 1992. A truncated activin receptor dominantly inhibits mesoderm induction and formation of axial structures in Xenopars embryos. Vature 359: 609-614.
    • Hemmati-Brivanlou, A., and Melton, D. A. 1994. Inhibition of activin receptor signalling promotes neuralization in Xenopus. Cell 77: 273-281.
    • Hemmati-Brivanlou, A., Kelly, O. G., and Melton, D. A. 1994. Follistatin, an antagonist of activin, is expressed in the Spemann Organiser and displays direct neuralizing activity. Cell 77: 283-295.
    • Iseki, S., Araga, A., Ohuchi, H., Nohno, T., Yoshioka, H., Hayashi, F. and Noji, S. 1996. Sonic hedgehog is expressed in epithelial cells during development of whisker, hair, and tooth. Biochem. Biophys. Res. Commun. 218: 688-693.
    • Kettunen, P. and Thesleff, 1. 1998. Expression and function of FGFs-4, -8, and -9 suggest functional redundancy and repetitive use as epithelial signals during tooth morphogenesis. Dev. Dyn. 211: 256-268.
    • Kollar, E. J. and Baird G. R. 1969. The influence of the dental papilla on the development of tooth shape in embryonic mouse tooth germs. J Embryol. Exp. Morph. 21: 131-148.
    • Kratochwil, K., Dull, M., Fari-as, I., Galceran, J. and Grosschedl, R. 1996. Lefl expression is activated by BMP-4 and regulates inductive tissue interactions in tooth and hair development. Genes Dev. 10: 1382-1394.
    • Lumsden A G. 1988. Spatial organisation of the epithelium and the role of neural crest cells in the initiation of the mammalian tooth germ. Development 103: 155-169.
    • Mackenzie, A., Leeming, G. L., Jowett. A. K., Ferguson, M. W. J. and Sharpe, P. T. 1991. The homeobox gene Hor-7. 1 has specific regional and temporal expression patterns during early murine craniofacial embryogenesis, especially tooth development in vivo and in vitro. Development 111: 269-285.
    • Matzuk, M. M., Kumar, T. R., Vassalli, A., Bickenbach, J. R., Roop, D. R., Jaenisch, R. and Bradley, A. 1995a. Functional analysis of activins during mammalian development. Nature 374: 354-356.
    • Matzuk, M. M., Kumar, and Bradley, A. 1995b. Different phenotypes for mice deficient in either activins or activin receptor type 11. Nature 374: 356-360.
    • Matzuk, M. M., Lu, N., Vogel, H., Selheyer, K., Roop, D. R., and Bradley, A. 1995c.
    • Multiple defects and perinatal death in mice deficient in follistatin. Nature 374: 360363.
    • Michel, U., Farnworth, P. and Finlay, J. P. 1993. Follistatins: more than follicle stimulating hormone suppressing proteins. Mol. Cell Endocrinol. 91: 1-11.
    • Mina M., and Kollar E. J. 1987. The induction of odontogenesis in non-dental mesenchyme combined with early murine mandibular arch epithelium. Arch. Oral. Biol. 32: 123-127.
    • Mucchielli, M., Mitsiadis, T. A., Raffo, S., Brunet, J., Proust, J. and Goridis, C. (1997) Mouse Otlx2/RIEG expression in the odontogenic epithelium precedes tooth iniation and requires mesenchymal derived signals for its maintenance. Dev. Biol. 189: 275284.
    • Nakamura. T., Takio, K., Eto, Y., Shibai, H., Titani, K. and Sugino, H. 1990. Activinbinding protein from rat ovary is follistatin. Science 247: 836-838.
    • Neubuser, A., Peters, H., Balling, R. and Martin, G. R. 1997. Antagonistic interactions between FGF and BMP signalling pathways: a mechanism for positioning the sites of tooth formation. Cell. 90: 247-255.
    • Page, K. M. 1990. Bone. In Theorv and Practice of Histological techniques. Third Edition. (ed J. D. Bancroft and A. Stevens), pp. 309-341. Churchill Livingstone, Edinburgh, London, Melbourne and New York.
    • Pownall, M. E., Tucker, A. S., Slack, J. M. W. and Isaacs, H. V. 1996. eFGF, Xcad3 and Hox genes form a molecular pathway that establishes the anteroposterior axis in Xenopus. Development 122: 3881-3892.
    • Qiu, M., Bufone, A., Ghattas, I., Menses, J. J., Sharpe, P. T., Presley, R., Pedersen, R. A.& Rubenstein, J. L. R. 1997. Role of Dlx-I and -2 in proximodistal patterning of the branchial arches: mutations alter morphogenesis of proximal skeletal elements derived from the first and second branchial arches. Dev. Biol. 185: 165-184.
    • Roberts, V. J. and Barth, S. L. 1994. Expression of messenger ribonucleic acids encoding the inhibin/activin system during mid- and late-gestation rat embryogenesis. Endocrinology 128: 914-923.
    • Roberts, V. J., Sawchenko, P. E. and Vale, W. W. 1991. Expression of inhibin/activin subunit messenger ribonucleic acids during rat embryogenesis. Endocrinology 128: 3122-3129.
    • Saxen, L. 1966. The effect of tetracyclin on osteogenesis in vitro. J. Exp. Zool. 162: 269-294.
    • Satokata, I. & Maas, R. 1994. Msx-I deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nature Genet. 6: 348-356.
    • Semina, E. V., Reiter, R., Leysens, N. J., Alward, W. L., Small, K. W., Datson, N. A., Siegel-Bartelt, J., Bierke-Nelson, D., Bitoun, P., Zabel, B. U., Carey, J. C. and Murray, J. C. 1996. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat. Genet. 14: 392399.
    • Thesleff, 1. and Sharpe, P. T. 1997. Signalling networks regulating dental development. Mech. Dev. 67:111-123.
    • Thesleff, I, Vaahtokari, A, & Partanen, A-M. 1995. Regulation of organogenesis. Common molecular mechanisms regulating the development of teeth and other organs. Int. J. Dev. Biol. 39: 35-50.
    • Thesleff, I., Vaahtokari, A., Vainio, S. and Jowett, A. 1996. Molecular mechanisms of cell and tissue interactions during early tooth development. Anatomical Record 245: 151-161.
    • Thomas, B. T., Porteus, M. H., Rubenstein, J. L. R. and Sharpe, P. T. 1995. The spatial localisation of Dlx-2 during tooth development. Conn. Tiss. Res. 32: 27-34.
    • Thomas, B. L., Tucker, A. S., Qui, M., Ferguson, C. A., Hardcastle, Z., Rubenstein, J. L. R. and Sharpe, P. T. 1997. Role of Dlx-1 and Dlx-2 genes in patterning of the murine dentition. Development 124: 4811-4818.
    • Thomsen, G., Woolf, T., Whitman, M., Sokol, S., Vaughan, J., Vale, W., and Melton, D. A. 1990. Activins are expressed early in Xenopus embryogenesis and can induce axial mesoderm and anterior structures. Cell 63: 485-493.
    • Tissier-Seta, J. P., Mucchielli, M. L., Mark, M., Mattei, M. G., Goridis, C. and Brunet, J. F. 1995. Barxl, a new mouse homeodomain transcription factor expressed in craniofacial ectomesenchyme and the stomach. Mech. Dev. 51: 3-15.
    • Trowell, O. A. 1959. The culture of mature organs in a synthetic medium. Exp. Cell Research 16: 118-147.
    • Vaahtokari, A., Vainio, S. and Thesleff, 1. 1991. Associations between transforming growth factor beta 1 RNA expression and epithelial-mesenchymal interactions during tooth morphogenesis. Development 113: 985-994.
    • Vaahtokari, A., Aberg, T., Jernvall, J., Keranen, S. and Thesleff, I. 1996 The enamel knot as a signalling center in the developing mouse tooth. Azfech. Dev. 54: 39-43.
    • Vainio, S., Karavanova, I., Jowett, A. and Thesleff, 1. 1993. Identification of BMP-4 as a signal mediating secondary induction between epithelial and mesenchymal tissues during early tooth development. Cell 75: 45-58.
    • Vale, W. W., Hseuh, A, Rivier, C. and Yu, J. 1990. The inhibin/activin family of hormones and growth factors. In: Peptide growth factors and their receptors II. (ed M. B. Sporn and A. B. Roberts), pp. 211-248. Springer-Verlag, Berlin. van Genderen, C., Okamura, R. M., Fari-as, I., Quo, R. G., Parslow, T. G., Bruhn, L. and Grosschedl, R. 1994. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev. 8: 2691-9703.
    • Wilkinson, D. G. 1995. In Situ Hybridisation, A practical approach. IRL Press, Oxford, UK.
    • Yamashita, H., ten Dijke, P., Huylebroeck, D., Sampath. T. K., Andries, M., Smith, J. C., Heldin, C.-H. and Miyazono, K. 1995. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell. Biol. 130: 217-226.
    • Phinney D G. J Cell Biochem Suppl 2002; 38:7-12
    • Krause D S. Gene Ther 2002 June; 9(11):754-8
    • Bianco P, Riminucci M, Gronthos S, Robey P G. Stem Cells 2001; 19(3):180-92
    • Prockop D J, Azizi S A, Colter D, Digirolamo C, Kopen G, Phinney D G. Biochem Soc Trans 2000; 28(4):341-5
    • Van Damme A, Vanden Driessche T, Collen D, Chuah M K. Curr Gene Ther 2002 May; 2(2): 195-209
    • Ballas C B, Zielske S P, Gerson S L. J Cell Biochem Suppl 2002; 38:20-8
    • Ito T, Suzuki A, Okabe M, Imai E, Hori M. Exp Nephrol 2001; 9(6):444-50
    • Minguell J J, Erices A, Conget P. Exp Biol Med (Maywood) 2001 June; 226(6):507-20
    • Koc O N, Lazarus H M. Bone Marrow Transplant 2001 February; 27(3):235-9
    • Caplan A I, Bruder S P. Trends Mol Med 2001 June; 7(6):259-64
    • Prockop D J. Science 1997 Apr. 4; 276(5309):71-4
    • Young, C. S., Terada, S., Vacanti, J. P., Honda, M., Bartlett, J. D., Yelick, P. C. (2002) Tissue engineering of complex tooth structures on biodegradable polymer scaffolds. J. Dent. Res. 81, 695-700.
    NUMBERED REFERENCES
    • 1. Tucker A S, Matthews K L and Sharpe P T. (1998). Science 282, 1136-1138
    • 2. Lumsden A S G (1988) Development 103, 122-169
    • 3. Thesleff I and Sharpe P T (1997) Mechs. Dev. 67, 111-123 4.
    • 4. Ferguson C A, Tucker A S, Christensen L, Lau A L, Matsuk M M and Sharpe P T (1998) Genes Dev. 12, 2636-2649
    • 5. Bagutti C, Wobus A M, Fassler R and Watt F M (1996) Dev. Biol. 179, 184-196
    • 6. Rathjen J, Lake J-A, Bettess M D, Washington J M, Chapmen G and Rathjen P D (1999) J. Cell Sci. 112, 601-612 7.
    • 7. Thomas B L, Tucker A S, Qiu M, Ferguson C A, Hardcastle Z, Rubenstein J L R and Sharpe P T (1997). Development 124, 4811-4818
    • 8. Ferguson C, Tucker A S and Sharpe P T (2000) Development in press.
    • 9. Sarkar L and Sharpe P T (2000) J Dent. Res. in press.
    • 10. Satokata I and Maas R (1994) Nat. Gen. 6, 348-356
    • 11. Hardcastle, Z, Mo, R., Hui, C-c and Sharpe P. T. (1998) Development 125, 2803 2811
    • 12. Lu M-F, Pressman C. Dyer R, Johnson R and Martin J F (1999) Nature 401, 276 278
    • 13. Lin C R, Kioussi C, O'Connell S, Briata P, Szeto D, Liu F, Izpisua-Belmonte J C and Rosenfeld M G (1999) Nature 401, 279-282
    • 14. Gage P J, Suh H and Camper S A (1999) Development 126, 4643-4651

Claims (18)

1. A method of generating a tooth primordium using bone marrow cells, the method comprising:
i) incubating the bone marrow cells in the presence of oral epithelial inductive signals for a time sufficient to produce a tooth progenitor cell;
ii) incubating the tooth progenitor cell in the presence of at least one epithelial cell for a time sufficient to produce a tooth primordium.
2. A method according to claim 1 wherein the bone marrow cells have not undergone purification for a particular cell type and/or have not undergone expansion to increase the proportion of a particular cell type present.
3. A method according to claim 1 wherein the bone marrow cells have undergone purification for a particular cell type and/or have undergone expansion to increase the proportion of a particular cell type present.
4. A method of generating a tooth progenitor cell, the method comprising incubating bone marrow cells in the presence of oral epithelial inductive signals to produce a tooth progenitor cell, wherein the bone marrow cells have not undergone purification for a particular cell type and/or expansion to increase the proportion of a particular cell type present.
5. A method according to claim 1 wherein the method comprises incubating the bone marrow cells in the presence of an embryonic oral epithelial cell, preferably provided in the form of oral epithelium, to produce the tooth progenitor cell.
6. A method according claim 1 wherein the method comprises incubating the bone marrow cells in the presence of inductive odontogenic cells which emulate the signalling characteristics of embryonic oral epithelial cells to thereby produce the tooth progenitor cell.
7. A method according to claim 1 wherein the method comprises incubating the bone marrow cells in the presence of protein-containing beads or protein-coated beads to emulate the signalling characteristics of embryonic oral epithelial cells to thereby produce the tooth progenitor cell.
8. A method of generating a tooth primordium according to claim 1 wherein the method comprises incubating the tooth progenitor cell in the presence of an oral epithelial cell, preferably provided in the form of oral epithelium, for a time sufficient to produce a tooth primordium.
9. A method of generating a tooth primordium according to claim 1 wherein the method comprises incubating the tooth progenitor cell in the presence of a non-oral epithelial cell for a time sufficient to produce a tooth primordium.
10. A method according to claim 9 wherein the method comprises incubating the tooth progenitor cell in the presence of an epithelial cell produced from an adult or embryonic stem cell for a time sufficient to produce a tooth primordium.
11. A method according to claim 9 wherein the method comprises incubating the tooth progenitor cell in the presence of an epithelial cell produced from an immortalised cell line for a time sufficient to produce a tooth primordium.
12. A method of generating a tooth primordium using bone marrow cells, the method comprising:
i) incubating the bone marrow cells in the presence of embryonic oral epithelium to produce a tooth progenitor cell;
ii) incubating the tooth progenitor cell in the presence of embryonic oral epithelium for a time sufficient to produce a tooth primordium.
13. A method according to claim 12 wherein the bone marrow cell are provided from a population of bone marrow cells which has not undergone expansion.
14. A tooth progenitor cell obtainable by a method according to claim 4.
15. A tooth primordium obtainable by a method according to claim 1.
16. A method of replacing a tooth in a subject in need of tooth replacement comprising the steps of:
i) providing a tooth primordium according to claim 15;
ii) implanting the tooth primordium into a mammalian kidney or into a space in the oral cavity and allowing the tooth primordium to develop into a tooth.
17. (canceled)
18. (canceled)
US10/546,495 2003-02-21 2004-02-17 Generating teeth from bone marrow cells Expired - Fee Related US7588936B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0304030.0 2003-02-21
GBGB0304030.0A GB0304030D0 (en) 2003-02-21 2003-02-21 Teeth
PCT/GB2004/000635 WO2004074464A1 (en) 2003-02-21 2004-02-17 Generating teeth from bone marrow cells

Publications (2)

Publication Number Publication Date
US20070003529A1 true US20070003529A1 (en) 2007-01-04
US7588936B2 US7588936B2 (en) 2009-09-15

Family

ID=9953453

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/546,495 Expired - Fee Related US7588936B2 (en) 2003-02-21 2004-02-17 Generating teeth from bone marrow cells

Country Status (8)

Country Link
US (1) US7588936B2 (en)
EP (1) EP1597358A1 (en)
JP (1) JP4365406B2 (en)
AU (1) AU2004213630B8 (en)
BR (1) BRPI0407633A (en)
CA (1) CA2556671A1 (en)
GB (1) GB0304030D0 (en)
WO (1) WO2004074464A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057542A1 (en) * 2004-09-02 2006-03-16 Odontis Ltd. Bone regeneration
CN103480040A (en) * 2013-09-27 2014-01-01 中国人民解放军第三军医大学第一附属医院 Bone matrix material containing various proteins secreted by umbilical cord mesenchymal stem cells and preparation method thereof
CN110496242A (en) * 2019-09-21 2019-11-26 天津赛德医药研究院有限公司 A kind of rapid hemostatic material based on nucleopore membranes
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286249A1 (en) * 2006-01-12 2008-11-20 Varney Timothy R Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20080138414A1 (en) * 2006-12-08 2008-06-12 Smith & Nephew, Inc. Methods of Regenerating Cartilage
EP2155860B1 (en) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US8470308B2 (en) * 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
IN2014CN04634A (en) 2011-12-28 2015-09-18 Amgen Inc
EP2633870B1 (en) 2012-02-29 2018-08-01 Technische Universität Berlin Method of preparing an artificial tooth primordium in vitro and artificial tooth primordium derived therefrom
US9782443B2 (en) * 2013-02-05 2017-10-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Preparing tooth-like structure using stem cell
CN105992816B (en) 2013-11-16 2018-04-17 泰尔茂比司特公司 Cell amplification in bioreactor
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN107177544A (en) * 2017-02-24 2017-09-19 首都医科大学附属北京口腔医院 BARX1 purposes
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP6841782B2 (en) 2018-03-28 2021-03-10 ヤンマーパワーテクノロジー株式会社 Autonomous driving system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003930D0 (en) 2000-02-18 2000-04-12 King S College London Cell
CA2510288A1 (en) 2004-09-02 2006-03-02 Odontis Ltd. Bone regeneration

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057542A1 (en) * 2004-09-02 2006-03-16 Odontis Ltd. Bone regeneration
US7497686B2 (en) * 2004-09-02 2009-03-03 Odontis Ltd. Bone regeneration
CN103480040A (en) * 2013-09-27 2014-01-01 中国人民解放军第三军医大学第一附属医院 Bone matrix material containing various proteins secreted by umbilical cord mesenchymal stem cells and preparation method thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN110496242A (en) * 2019-09-21 2019-11-26 天津赛德医药研究院有限公司 A kind of rapid hemostatic material based on nucleopore membranes

Also Published As

Publication number Publication date
JP2006518210A (en) 2006-08-10
AU2004213630B2 (en) 2007-11-29
JP4365406B2 (en) 2009-11-18
US7588936B2 (en) 2009-09-15
EP1597358A1 (en) 2005-11-23
BRPI0407633A (en) 2006-02-21
GB0304030D0 (en) 2003-03-26
WO2004074464A1 (en) 2004-09-02
CA2556671A1 (en) 2004-09-02
AU2004213630B8 (en) 2008-09-25
AU2004213630A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US7588936B2 (en) Generating teeth from bone marrow cells
Yang et al. Tooth root regeneration using dental follicle cell sheets in combination with a dentin matrix-based scaffold
US7498168B2 (en) Tooth progenitor cell and method for its production
AU2005202726B2 (en) Bone regeneration
Zhai et al. Isolation and culture of hair cell progenitors from postnatal rat cochleae
Kuznetsov et al. In vivo bone formation by progeny of human embryonic stem cells
CA2522669C (en) Postnatal stem cells and uses thereof
JP5069572B2 (en) Method for producing mesenchymal cells, method for producing teeth, and mesenchymal cells for tooth formation
EP2274419B1 (en) Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations
Farea et al. Synergistic effects of chitosan scaffold and TGFβ1 on the proliferation and osteogenic differentiation of dental pulp stem cells derived from human exfoliated deciduous teeth
JP5926240B2 (en) Chondrogenic progenitor cells, protocol for cell derivation and use thereof
JP4714741B2 (en) Teeth regeneration method
US8030072B2 (en) Method of isolating epidermal neural crest stem cells
US9085754B2 (en) Isolated population of cells and methods of generating and using same
Zhao et al. Muscle-derived stem cells differentiate into functional smooth muscle cells for ureter tissue engineering: An experimental study
Yang Odontogenic Induction Capacity of in Vitro Expanded Dental Mesenchymal Cells in Whole Tooth Bioengineering
Whitehouse Hair follicle germinative epidermal cells: a molecular study
Münst Neural crest development in a human embryonic stem cell-based model system

Legal Events

Date Code Title Description
AS Assignment

Owner name: ODONTIS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHARPE, PAUL T.;REEL/FRAME:017662/0018

Effective date: 20060302

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130915